肠道细菌影响肿瘤免疫微环境：会影响免疫疗法的疗效吗？
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not？.
机构信息
Department of Radiation Oncology & Therapy, Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University , Changchun, China.
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University , Changchun, China.
出版信息
Gut Microbes. 2020 Jul 3;11(4):691-705. doi: 10.1080/19490976.2020.1739794. Epub 2020 Mar 27.
Abstract
Immunotherapy using immune-checkpoint inhibitors is revolutionizing oncotherapy. However, the application of immunotherapy may be restricted because of the lack of proper biomarkers in a portion of cancer patients. Recently, emerging evidence has revealed that gut commensal bacteria can impact the therapeutic efficacy of immune-checkpoint inhibitors in several cancer models. In addition, testing the composition of gut bacteria provides context for prediction of the efficacy and toxicity of immunotherapy. In this review, we discuss the impacts of gut commensal bacteria on the tumoral immune milieu, highlighting some typical bacteria and their associations with immunotherapy.
摘要
免疫检查点抑制剂的免疫疗法正在彻底改变肿瘤治疗。然而，由于一部分癌症患者缺乏适当的生物标志物，免疫疗法的应用可能受到限制。最近，新出现的证据表明，肠道共生细菌可以影响几种癌症模型中免疫检查点抑制剂的治疗效果。此外，检测肠道细菌的组成可以为预测免疫疗法的疗效和毒性提供依据。在这篇综述中，我们讨论了肠道共生细菌对肿瘤免疫微环境的影响，强调了一些典型细菌及其与免疫疗法的关联。
相似文献
1
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not？.肠道细菌影响肿瘤免疫微环境：会影响免疫疗法的疗效吗？
Gut Microbes. 2020 Jul 3;11(4):691-705. doi: 10.1080/19490976.2020.1739794. Epub 2020 Mar 27.
2
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.调控肠道菌群以增强免疫检查点抑制剂的治疗效果。
Front Immunol. 2021 Jun 29;12:669150. doi: 10.3389/fimmu.2021.669150. eCollection 2021.
3
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.肠道微生物组在癌症免疫治疗中的调节作用：免疫检查点抑制剂阻断的新范例。
Cancer Med. 2021 Feb;10(3):1141-1154. doi: 10.1002/cam4.3694. Epub 2020 Dec 25.
4
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.肠道细菌组成驱动肾细胞癌患者对癌症免疫疗法的原发性耐药性。
Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4.
5
Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?肠道微生物衍生代谢物对免疫检查点抑制剂治疗的影响：敌是友？
Molecules. 2022 Jul 27;27(15):4799. doi: 10.3390/molecules27154799.
6
Gut microbiome and cancer immunotherapy.肠道微生物组与癌症免疫治疗。
J Cell Physiol. 2020 May;235(5):4082-4088. doi: 10.1002/jcp.29359. Epub 2019 Oct 29.
7
Association of the gut microbiome with cancer immunotherapy.肠道微生物组与癌症免疫疗法的关联。
Int J Clin Oncol. 2023 Mar;28(3):347-353. doi: 10.1007/s10147-022-02180-2. Epub 2022 May 14.
8
The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.肠道微生物群提高免疫检查点抑制剂免疫疗法治疗肿瘤的疗效：从关联到因果关系。
Cancer Lett. 2024 Aug 28;598:217123. doi: 10.1016/j.canlet.2024.217123. Epub 2024 Jul 20.
9
The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.MITRE 试验方案：一项评估癌症患者接受免疫检查点抑制剂治疗时微生物组作为疗效和毒性生物标志物的研究。
BMC Cancer. 2022 Jan 24;22(1):99. doi: 10.1186/s12885-021-09156-x.
10
Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination.共生微生物组在免疫靶向干预期间的免疫调节：关注癌症免疫检查点抑制剂治疗和疫苗接种。
Front Immunol. 2021 May 13;12:643255. doi: 10.3389/fimmu.2021.643255. eCollection 2021.
引用本文的文献
1
Diagnostic value of alpha-fetoprotein and prothrombin induced by vitamin K absence-II in serum, bile, and feces in hepatocellular carcinoma.血清、胆汁和粪便中甲胎蛋白及维生素K缺乏诱导蛋白-II在肝细胞癌中的诊断价值
World J Gastrointest Oncol. 2025 May 15;17(5):105311. doi: 10.4251/wjgo.v17.i5.105311.
2
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges.推进乳腺癌治疗：免疫疗法和癌症疫苗在克服治疗挑战中的作用。
Vaccines (Basel). 2025 Mar 24;13(4):344. doi: 10.3390/vaccines13040344.
3
Advances in research on the intestinal microbiota in the mechanism and prevention of colorectal cancer (Review).肠道微生物群在结直肠癌发生机制及预防中的研究进展（综述）
Mol Med Rep. 2025 May;31(5). doi: 10.3892/mmr.2025.13498. Epub 2025 Mar 21.
4
The Role of Gut Microbiota in Tumor Immunotherapy.肠道微生物群在肿瘤免疫治疗中的作用。
J Immunol Res. 2021 Aug 26;2021:5061570. doi: 10.1155/2021/5061570. eCollection 2021.
本文引用的文献
1
Immuno-oncology drug development goes global.免疫肿瘤学药物研发走向全球。
Nat Rev Drug Discov. 2019 Nov;18(12):899-900. doi: 10.1038/d41573-019-00167-9.
2
IgA and the intestinal microbiota: the importance of being specific.IgA 与肠道微生物群：具体问题具体分析的重要性。
Mucosal Immunol. 2020 Jan;13(1):12-21. doi: 10.1038/s41385-019-0227-4. Epub 2019 Nov 18.
3
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.抗PD-1或抗PD-L1疗法生物标志物的不断演变格局
J Clin Med. 2019 Sep 25;8(10):1534. doi: 10.3390/jcm8101534.
4
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.肿瘤微生物组多样性和组成影响胰腺癌预后。
Cell. 2019 Aug 8;178(4):795-806.e12. doi: 10.1016/j.cell.2019.07.008.
5
Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways.齿双歧杆菌通过自噬和钙信号通路强化肠道黏膜层。
mBio. 2019 Jun 18;10(3):e01087-19. doi: 10.1128/mBio.01087-19.
6
Daily Sampling Reveals Personalized Diet-Microbiome Associations in Humans.每日采样揭示人类饮食-微生物组的个性化关联。
Cell Host Microbe. 2019 Jun 12;25(6):789-802.e5. doi: 10.1016/j.chom.2019.05.005.
7
Activated Peyer's patch B cells sample antigen directly from M cells in the subepithelial dome.活化的派尔集合淋巴结 B 细胞直接从黏膜下丘的 M 细胞中取样抗原。
Nat Commun. 2019 Jun 3;10(1):2423. doi: 10.1038/s41467-019-10144-w.
8
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.肠道微生物组的多样性与中国 NSCLC 患者对抗 PD-1 免疫治疗的良好反应相关。
J Thorac Oncol. 2019 Aug;14(8):1378-1389. doi: 10.1016/j.jtho.2019.04.007. Epub 2019 Apr 23.
9
Gut Microbiota Regulation of T Cells During Inflammation and Autoimmunity.肠道微生物群在炎症和自身免疫中对 T 细胞的调节。
Annu Rev Immunol. 2019 Apr 26;37:599-624. doi: 10.1146/annurev-immunol-042718-041841.
10
Akkermansia muciniphila is a promising probiotic.黏蛋白阿克曼菌是一种有前景的益生菌。
Microb Biotechnol. 2019 Nov;12(6):1109-1125. doi: 10.1111/1751-7915.13410. Epub 2019 Apr 21.
Zotero 插件